Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Maravai LifeSciences Holdings, Inc.
MRVI
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.7B
$6.05
▼ -1.55%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$1.99 - $6.55
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 132.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary CleanCap capping technology for mRNA therapeutics with high barriers to entry
- Integrated product portfolio addressing multiple phases of drug development from synthesis to manufacturing quality control
- Strong customer relationships with major pharmaceutical and biotech companies creating switching costs and recurring revenue
- Specialized expertise in nucleic acid chemistry and biologics safety testing with limited direct competitors
Bear Case
1 risk
- Low volatility (beta 0.7).
Growth
Stable outlook
Expansion of mRNA therapeutic pipeline globally with increased investment in vaccine and therapeutic development
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+108.5% over 3m
Quality
Stable
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying MRVI right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 11, 2026
MAY 7, 2026
Reported EPS of $0.01 vs -$0.05 consensus (+120.0% surprise). Revenue of $65.8M vs $53.0M expected (+24.2%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+120.0%
Next: May 11, 2026
Revenue trend · last 8Q
—
—
-24%
-27%
-35%
-36%
-12%
+41%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$73.4M
$65.2M
$56.4M
$46.9M
$47.4M
$41.6M
$49.9M
$65.8M
Margins · last 8Q
Gross
—
Operating
—
Profit
-5.7%
Wall Street consensus
2 analysts · 50% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
50%
Hold
0%
Sell
50%
Median Price Target
$6.00
▼ -0.9% vs $6.05
Latest: UBS · Jun 3, 2026
1 analyst covering